Dexmedetomidine - 10mM in DMSO, high purity , CAS No.113775-47-6(DMSO)

Item Number
D407960
Grouped product items
SKUSizeAvailabilityPrice Qty
D407960-1ml
1ml
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$277.90

α-adrenergic receptor Selective Inhibitors | Agonists | Antagonists

Basic Description

Specifications & PurityMoligand™, 10mM in DMSO
Biochemical and Physiological MechanismsDexmedetomidine is a sedative medication used by intensive care units and anesthetists.
Storage TempStore at -80°C
Shipped InIce chest + Ice pads
GradeMoligand™
Product Description

Information

Dexmedetomidine is a sedative medication used by intensive care units and anesthetists.
In vitro

Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction.

In vivo


Cell Data

cell lines:

Concentrations:

Incubation Time:

Powder Purity:≥99%

Associated Targets(Human)

CYP1A2 Tchem Cytochrome P450 1A2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CYP3A4 Tclin Cytochrome P450 3A4 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CYP2C9 Tchem Cytochrome P450 2C9 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADRA2C Tclin Alpha-2C adrenergic receptor (3 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADRA2A Tclin Alpha-2A adrenergic receptor (5 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ADRA1D Tclin Alpha-1D adrenergic receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

Canonical SMILES CC(C1=CN=C[NH]1)C2=CC=CC(=C2C)C
Molecular Weight 200.28

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 33 mg/mL (198.53 mM);    

Related Documents

Citations of This Product

1. Gao Yang, Kang Kai, Liu Yan-song, Li Na-na, Han Qiu-yuan, Liu Hai-tao, Kong Wei-lan, Zhang Xing, Huang Rui, Yang Zhen-yu, Qi Zhi-dong, Zheng Jun-bo, Li Ming, Wang Hong-liang, Li Jia-yu, Liu Rui-jin, Wang Si-cong, Zhang Wei-hua, Zhao Ming-yan, Yu Kai-jiang.  (2021)  Mechanisms of Renal-Splenic Axis Involvement in Acute Kidney Injury Mediated by the α7nAChR-NF-κB Signaling Pathway.  INFLAMMATION,  44  (2): (746-757).  [PMID:33141376] [10.1007/s10753-020-01374-y]

References

1. Gao Yang, Kang Kai, Liu Yan-song, Li Na-na, Han Qiu-yuan, Liu Hai-tao, Kong Wei-lan, Zhang Xing, Huang Rui, Yang Zhen-yu, Qi Zhi-dong, Zheng Jun-bo, Li Ming, Wang Hong-liang, Li Jia-yu, Liu Rui-jin, Wang Si-cong, Zhang Wei-hua, Zhao Ming-yan, Yu Kai-jiang.  (2021)  Mechanisms of Renal-Splenic Axis Involvement in Acute Kidney Injury Mediated by the α7nAChR-NF-κB Signaling Pathway.  INFLAMMATION,  44  (2): (746-757).  [PMID:33141376] [10.1007/s10753-020-01374-y]

Solution Calculators